Moderna, Merck announce 3-year data for mRNA-4157 (V940) in combo with Keytruda demonstrated sustained improvement in RFS & DMFS v/s Keytruda in patients with high-risk stage III/IV melanoma following

Moderna, Inc. and Merck, known as MSD outside of the United States and Canada, announced the first presentation of results from a planned analysis from the phase 2b randomized KEYNOTE-942/mRNA-4157-P201 [...]